IPP Bureau
AWS partners with Pfizer to accelerate drug development
By IPP Bureau - December 06, 2021
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
Roche develops tests to identify Omicron variant
By IPP Bureau - December 06, 2021
Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant, as they continue to offer new and accurate detection solutions
Lilly's bamlanivimab with etesevimab authorized for emergency use in Covid-19 patients under 12
By IPP Bureau - December 06, 2021
Expanded EUA includes both treatment of patients with Covid-19 and post-exposure prophylaxis (PEP) in high-risk pediatric and infant patients
Roche to launch SARS-CoV-2 and flu A/B Rapid Antigen Test in countries accepting the CE mark
By IPP Bureau - December 06, 2021
The combination rapid antigen test quickly differentiates between SARS-CoV-2 and influenza viruses A and B infections, with results ready in less than 30 minutes, allowing informed decisions on patient and pandemic management decisions
J&J booster after the two-dose Pfizer-BioNTech vaccine increases antibody and T-cell responses
By IPP Bureau - December 06, 2021
These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv
Ophthalmologists converge in Chennai to discuss latest innovations
By IPP Bureau - December 05, 2021
IIRSI 2021 aims to bring together ophthalmologists across India and abroad to discuss the advancement in technology and their experience in IOL implantation and Refractive Surgery
Narayana Hrudayalaya to open a hospital in Punjab
By IPP Bureau - December 05, 2021
The hospital is scheduled to open in 2024 with a bed capacity of 225
Lupin and Biomm tie-up for pegfilgrastim in Brazil
By IPP Bureau - December 05, 2021
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
SPARC to licence Biomodifying’s IP
By IPP Bureau - December 05, 2021
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
Morpen gets U.S. FDA approval for Fexofinadine
By IPP Bureau - December 05, 2021
Fexofinadine is the most widely used, second-generation antihistamine drug for the treatment of allergy symptoms and hay fever
Apollo Health Ventures closes US $ 180 million fund
By IPP Bureau - December 05, 2021
The fund aims at investing in companies that extends human healthspan
Motherhood Hospitals opens second center in Pune
By IPP Bureau - December 05, 2021
The first hospital in Kharadi launched three years ago has made a significant difference to women and children's health
Monthly production capacity of Covishield and Covaxin touches 90% : Govt
By IPP Bureau - December 05, 2021
Serum has a capacity of 250-275 million whereas Bharat Biotech has a capacity of 50-60 million
Unichem Labs gets ANDA approval for schizophrenia medicine
By IPP Bureau - December 03, 2021
The product will be commercialized from Unichem's Ghaziabad plant
Biocon Pharma receives ANDA approval for Mycophenolic acid
By IPP Bureau - December 03, 2021
This further adds to Biocon’s portfolio of vertically integrated complex drug products
